In addition, our findings suggest that targeting the SKP2–FOXA1 interplay through SKP2 inhibition during advanced stages of PCa is more beneficial than targeting these interactions during earlier stages for restoring luminal positive cells, suggesting a possible clinical application. The gene discussed is FOXA1; the disease is posterior cortical atrophy.